IMM-6-415 is under clinical development by Immuneering and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 36% phase transition ...

IMM-6-415 is under clinical development by Immuneering and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% ...

Immuneering Corporation IMRX soared 41.3% on Friday after it reported promising early response data from the first five patients of an ongoing early to mid-stage ...

MISO's Long Range Transmission Plan (LRTP) faces new challenges as it moves toward the approval of its $20 billion Tranche 2 ...

Immuneering Corporation (NASDAQ:IMRX) released initial response data from the first five patients treated with IMM-1-104 in ...

Immuneering Corporation IMRX soared 41.3% on Friday after it reported promising early response data from the first five patients of an ongoing early to mid-stage study evaluating IMM-1-104 ...

Spoon Labs’ most recent financing was in 2019, when it raised 45 billion won from investors including Naver, IMM Investment ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

To date, the combination of IMM-1-104 plus modified gemcitabine/nab-paclitaxel has been observed to be well tolerated. The study included one Complete Response out of ...